Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
Status:
Not yet recruiting
Trial end date:
2026-11-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look at pulmonary exacerbations in people with cystic
fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a
vein (intravenous or IV). A pulmonary exacerbation is a worsening of respiratory symptoms in
people with CF that needs medical intervention. Both doctors and CF patients are trying to
understand the best way to treat pulmonary exacerbations. This study is trying to answer the
following questions about treating a pulmonary exacerbation:
- Do participants have the same improvement in lung function and symptoms if they are
treated with one type of antibiotic (called beta-lactams or β-lactams) versus taking two
different types of antibiotics (tobramycin and β-lactams)?
- Is taking one type of antibiotic just as good as taking two types?
Phase:
Phase 4
Details
Lead Sponsor:
Chris Goss
Collaborators:
Cystic Fibrosis Foundation Medical University of South Carolina University of Washington